[pliftkl]

While I realize that this particular drug is just an example, we could run some numbers here. The current owner of the drug made $27M in sales this year in the US. At $10k per 30 day supply, that implies that there are at most 2700 people in the US who use this drug (if all of them used it only once per year). If this is a drug that most of its users take all year, then we're now talking about a drug that is taken by very few people every year. The $5 French price point wouldn't be worthwhile for any US based pharma company to take on. This isn't a defense of anyone's pricing model, but I could see very easily why pricing models for very rarely prescribed drugs would naturally start to shoot through the roof in the US. Why is it tolerated? Most people don't feel like they are impacted by it.